Saponins from Chenopodium quinoa Willd. husks alleviated high‐fat‐diet‐induced hyperlipidemia via modulating the gut microbiota and multiple metabolic pathways

Abstract

AbstractBackgroundHyperlipidemia is characterized by abnormally elevated blood lipids. Quinoa saponins (QS) have multiple pharmacological activities, including antitumor, bactericidal and immune‐enhancing effects. However, the lipid‐lowering effect and mechanisms of QS in vivo have been scarcely reported.MethodsThe effect of QS against hyperlipidemia induced by high‐fat diet in rats was explored based on gut microbiota and serum non‐targeted metabolomics.ResultsThe study demonstrated that the supplementation of QS could reduce serum lipids, body weight, liver injury and inflammation. 16S rRNA sequencing demonstrated that QS mildly increased alpha‐diversity, altered the overall structure of intestinal flora, decreased the relative richness of Firmicutes, the ratio of Firmicutes/Bacteroidetes (P < 0.05) and increased the relative richness of Actinobacteria, Bacteroidetes, Bifidobacterium, Roseburia and Coprococcus (P < 0.05). Simultaneously, metabolomics analysis showed that QS altered serum functional metabolites with respect to bile acid biosynthesis, arachidonic acid metabolism and taurine and hypotaurine metabolism, which were closely related to bile acid metabolism and fatty acid β‐oxidation. Furthermore, QS increased protein levels of farnesoid X receptor, peroxisome proliferator‐activated receptor α and carnitine palmitoyltransferase 1, which were related to the screened metabolic pathways. Spearman correlation analysis showed that there was a correlation between gut microbiota and differential metabolites.ConclusionQS could prevent lipid metabolism disorders in hyperlipidemic rats, which may be closely associated with the regulation of the gut microbiota and multiple metabolic pathways. This study may provide new evidence for QS as natural active substances for the prevention of hyperlipidemia. © 2023 Society of Chemical Industry.